Those who invested in Formycon (ETR:FYB) five years ago are up 114%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...
Source: yahoo.com
📰 Formycon Ag News
Formycon Ag News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Formycon Ag. Real-time updates on events, politics, business and more.
Revenues Not Telling The Story For Formycon AG (ETR:FYB)
Formycon AG's ( ETR:FYB ) price-to-sales (or "P/S") ratio of 13.2x might make it look like a strong sell right now...
Source: yahoo.com
Investegate |Formycon AG Announcements | Formycon AG: Formycon AG upsizes capital increase from authorized capital following strong demand
Investegate announcements from Formycon AG, Formycon AG upsizes capital increase from authorized capital following strong demand
United States Corporate Communications European Parliament Ewvy Formycon Or Company Market Scale Of The Frankfurt Stock Exchange Active Ownership Capital
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Investegate announcements from Formycon AG, Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
United States Johnson Stelara Fresenius Kabi Corporate Communications Market Scale Of The Frankfurt Stock Exchange Latin America
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
Investegate announcements from Formycon AG, Formycon AG plans capital increase of approx. 5% of the share capital by way of an accelerated bookbuilding procedure to finance further growth
United States Hauck Aufh Management Board Of The Company European Parliament Ewvy Formycon Or Company Stock Exchange
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
Investegate announcements from Formycon AG, Formycon announces EU-Approval of FYB201/Ranivisio®1 a biosimilar to Lucentis®2
Polpharma Biologics Corporate Communications European Union European Commission Market Scale Of The Frankfurt Stock Exchange Genentech Inc
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
Investegate announcements from Formycon AG, Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2
United States Choroidal Neovascularization Polpharma Biologics Group Corporate Communications Coherus Biosciences Inc Market Scale Of The Frankfurt Stock Exchange
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: FYB201, Formycon's biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA
Investegate announcements from Formycon AG, FYB201, Formycons biosimilar for Lucentis® (ranibizumab), receives CHMP recommendation from EMA
European Commission Genentech Inc Teva Pharmaceutical Industries Ltd European Union Corporate Communications Market Scale Of The Frankfurt Stock Exchange
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
Investegate announcements from Formycon AG, Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
Source: investegate.co.uk
Investegate |Formycon AG Announcements | Formycon AG: Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Investegate announcements from Formycon AG, Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
Corporate Communications Cell Therapy Pte Ltd Hoc Announcement Concludes Collaboration License Agreement Asia Pacific
Source: investegate.co.uk